Tech Center 1600 • Art Units: 1623 1626
This examiner grants 80% of resolved cases
Jed A. Kucharczk serves in Tech Center 1600 and Art Unit 1623, where they have overseen 96 resolved cases. The examiner demonstrates an allowance rate pct of 80.2, suggesting a high frequency of grants for applications assigned to this office. This 80.2 allowance rate pct establishes a strong probability of success for practitioners navigating the requirements of Tech Center 1600.
The interview lift pct of 16.7 indicates that conducting an interview provides a measurable benefit to the prosecution process. While the 80.2 allowance rate pct is already high, the 16.7 lift suggests that personal interaction can further clarify claims or resolve examiner concerns. In Art Unit 1623, the 16.7 interview lift pct serves as a useful tool for applicants seeking to expedite their path to a grant.
The median days to allowance for cases under this examiner is 1021. This duration of 1021 days offers a benchmark for applicants to estimate the time required to reach a final resolution. With 96 resolved cases, the data provides a consistent view of the examiner's procedural habits and timelines. Practitioners should factor the 1021 median days to allowance into their long-term planning for intellectual property assets.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18547800 | MELANOCORTIN-4 RECEPTOR AGONIST | Non-Final OA | LG CHEM, LTD. |
| 18194840 | HYPOTONIC MICROBICIDAL FORMULATIONS AND METHODS OF USE | Final Rejection | The Johns Hopkins University |
| 18548109 | SN-38 DERIVATIVE, NANO-PARTICLES CONTAINING SAID DERIVATIVE, MEDICINE, AND METHOD FOR PRODUCING SAID NANO-PARTICLES | Final Rejection | JAPAN SCIENCE AND TECHNOLOGY AGENCY |
| 19220457 | METHODS OF DISPERSING ARIPIPRAZOLE INJECTABLE PREPARATIONS | Final Rejection | Otsuka Pharmaceutical Co., Ltd. |
| 18556711 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Non-Final OA | Nanyang Technological University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy